Financial GuidanceCompany management increased financial guidance for full-year 2025, primarily to reflect higher royalties from new products Qarziba (Recordati) and Filspari (Travere).
Market UncertaintyInvestor interest in royalty aggregators like Ligand has increased due to uncertainties in the equity-raising market for smaller biotech companies.
Revenue GrowthRoyalty revenue growth from recently launched or acquired products are expected to boost financial results for LGND in 2H25, along with new sources of revenue brought on board early in the third quarter.